Sydney: Sleep-breathing device maker ResMed plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style weight loss drugs for apnea, calling ...
SYDNEY, Feb 3 (Reuters) - Sleep-breathing device maker ResMed (RMD.N), opens new tab plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style ...
SYDNEY, Feb 3 (Reuters) - Sleep-breathing device maker ResMed plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style weight loss drugs for ...
ResMed Inc. (NYSE:RMD) presented its second-quarter fiscal year 2026 results on January 29, 2026, showcasing strong financial performance with revenue growth of 9% at constant currency. Despite ...
Jan 29 (Reuters) - Medical device maker ResMed (RMD.N), opens new tab on Thursday beat Wall Street estimates for second-quarter profit on the back of strong demand for its devices used to manage sleep ...
Resmed believes its artificial intelligence-powered approach to personalizing the settings of its connected CPAP machines can lead to better sleep for people with obstructive apnea. Now the FDA has ...
Resmed Inc.’s RMD adjusted earnings per share (EPS) in the first quarter of fiscal 2026 were $2.55, up 15.9% year over year. The metric beat the Zacks Consensus Estimate by 2.41%. The adjustments ...
Fractus, a company specializing in geometry-based antenna technology and IP licensing, has filed a patent infringement suit against respiratory leader ResMed. The complaint was filed in the United ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results